News

Glonghui, March 27｜Sony Group has decided to increase the prices of PS5, PS5 PRO, and the PlayStation Portal controller globally, effective from April 2. In the US market, the price of the PS5 has been raised to $649.99, the PS5 Digital Edition to $599.99, and the PS5 Pro to $899.99.

Glonhui March 27｜Huaying Group (AXG.US) officially announced today the initiation and establishment of the "Global Token Hub Alliance." As the world's first industry collaboration platform focused on the AI Token field, this alliance aims to deeply align with the global development trends of AI computing power compliance, scalability, and practical application, building a new digital finance ecosystem for the Web 4.0 era.The alliance will leverage Huaying Group and its global strategic partners' underlying technological strengths and extensive ecosystem connectivity in the Token sector to integrate upstream and downstream industry resources. Its core mission is to promote the compliant application and ecosystem co-construction of token assets, injecting powerful momentum into the development of global digital finance and the AI industry.By attracting leading global computing power providers, model developers, and AI application enterprises to join, the alliance will assist Hong Kong in refining its AI industry chain and further consolidate and enhance its competitiveness as an international financial center in the Web 4.0 era.Reportedly, the Global Token Hub Alliance will be deeply linked with Tokenthon, Huaying Group's newly established global developer community competition. The alliance will provide participating teams with extremely low-cost token resource support, and AX Ventures will offer dedicated funding assistance. Several industry-leading institutions have already expressed intentions to join, collaboratively promoting the global implementation of the token economy.

This drug is intended for the treatment of patients with relapsed extensive-stage small cell lung cancer who have previously received systemic therapy. This recommendation is based on pivotal clinical research data, showing that Tarlatamab, as a bispecific T-cell engager antibody, can significantly activate the patient's own immune system to attack tumor cells. If ultimately approved by the European Commission, it will become the first targeted immunotherapy for this indication, providing a new treatment option for advanced lung cancer patients with a very poor prognosis.